Pfizer Covid vaccine 95% effective and safe, final analysis shows

Last week, Pfizer and its German associate BioNTech reported that their vaccine was 90 percent effective.

Pfizer Covid vaccine 95% effective and safe, final analysis shows
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syring...

Pfizer Covid vaccine is 95% effective and safe, final analysis has shown. The final review of the vaccine created by Pfizer and BioNTech proved that it is safe and 95 percent effective in stopping Covid-19 infection. This development will pave the way for its eventual authorization and deployment among the global population.

The mRNA-based candidate passed its full safety tests, Pfizer said. Also, it is now ready for submission for commercial clearance to the regulatory authorities.

Last week, Pfizer and its German associate BioNTech reported that their vaccine was 90 percent effective. The rate was dependent on the phase-three research analysis of 94 infections among participants.

More

They registered 170 cases, helping the two companies offer a better verdict on the efficacy and protection of their candidate.

Just eight of those volunteers who tested positive for Covid-19 got the vaccine. They identified the remaining 162 infections among the placebo group.

For the approval of the vaccine “within days,” Pfizer will send its large-scale trial data to the U.S. Food and Drug Administration.

Furthermore, the European Medicines Agency (EMA) reported that it had already obtained a rolling review trial from Pfizer and BioNTech. However, they are yet to seek that permission.

Pfizer to supply the U.K. 10 million doses this December

The U.K. government already secured a total of 40 million doses of the vaccine. Meanwhile, they will be getting 1o million doses by the end of the year if the vaccine wins approval.

The vaccine offers protection after 28 days of administering it. Also, it consists of two doses, which means that up to five million Britons could get it during the winter period.

Ugur Sahin, BioNTech’s co-founder, said the data suggest that people could achieve a high degree of safety against Covid-19. He also added that ‘that’s quite easily’ after the first dose.

“I’m optimistic, though not yet confident, that by Christmas, we will start getting some vaccinations,” said Jonathan Van-Tam, deputy chief medical officer of England, last week.

Have a tip we should know? tips@rhd.news

Follow @rushhourdaily: